Quotes 5-day view Delayed Nasdaq
343 801 Volume
Estimated financial data (e) (USD)
Net income 2022
Net cash position 2022
P/E ratio 2022
Net income 2023
Net cash position 2023
P/E ratio 2023
1 576 M
1 576 M
EV / Sales 2022
EV / Sales 2023
Nbr of Employees
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In...
Ratings of Agios Pharmaceuticals, Inc.
All news about AGIOS PHARMACEUTICALS, INC.
12/07 Transcript : Agios Pharmaceuticals, Inc. Presents at Bank of America 2022 Vir..
12/06 Agios Pharmaceuticals, Inc. : Change in Directors or Principal Officers, Financial Stateme..
12/06 Agios Appoints Tsveta Milanova as Chief Commercial Officer
12/06 Agios Pharmaceuticals, Inc. Appoints Tsveta Milanova as Chief Commercial Officer, Effec..
12/01 JPMorgan Chase Adjusts Price Target on Agios Pharmaceuticals to $33 From $48, Maintains..
11/30 Agios to Participate in December Investor Conference
11/18 North American Morning Briefing: Stocks to Edge -2-
11/17 Goldman Sachs Upgrades Agios Pharmaceuticals to Neutral from Sell, Lifts Price Target t..
11/11 Agios Pharmaceuticals, Inc. - PYRUKYND Approved in the EU for the Treatment of Pyruvate..
11/10 PYRUKYND« (mitapivat) Approved in the EU for the Treatment of Pyruvate Kinase (PK) Defi..
11/10 Agios Pharmaceutical's PYRUKYND« Approves in the EU for the Treatment of Pyruvate Kinas..
11/04 RBC Trims Price Target on Agios Pharmaceuticals to $43 From $44, Maintains Outperform R..
11/03 AGIOS PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Conditio..
11/03 Agios Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Mon..
11/03 Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Chroni..
News in other languages on AGIOS PHARMACEUTICALS, INC.
Analyst Recommendations on AGIOS PHARMACEUTICALS, INC.
ETFs positioned on AGIOS PHARMACEUTICALS, INC. ETFs and Trackers with Trackinsight
Chart AGIOS PHARMACEUTICALS, INC.
Technical analysis trends AGIOS PHARMACEUTICALS, INC.
Short Term Mid-Term Long Term Trends Neutral Bullish Bullish
Number of Analysts
Last Close Price
Average target price
Spread / Average Target